SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know

  • SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc MRK from a potential acquisition of Seagen Inc SGEN.
  • The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive.
  • Related: Merck Shows Takeover Interest In Seagen: WSJ.
  • According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in 2023, 2024, and 2025 from that expected for standalone Merck. 
  • But, in the longer term, the positive impact on free cash flow (FCF) generation, top & bottom-line growth, and partial mitigation of Merck's Keytruda loss of exclusivity in 2028 are supportive of the deal. 
  • The analysts expect lower Keytruda revenue estimate dependence in 2028 to 42.5% from 48.4%. 
  • Further, a DCF analysis (2024-2032E) suggests that the combined entity could be worth $136/share (~$388 billion equity value). SVB forecasts Merck at $104/share. 
  • The combined entity can generate an estimated FCF of ~$247 billion from 2024 to 2032 versus around $176 billion for standalone Merck.
  • But increasing debt costs, and decreasing equity values, could lead some investors to pause, despite the longer-term impact on FCF, SVB writes.
  • Price Action: MRK shares are up 2.32% at $86.58, and SGEN shares are up 1.59% at $168.08 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLarge CapM&ANewsHealth CareRumorsAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!